|
Scripts
Mar 28, 2015 8:51:18 GMT -5
Post by krj00 on Mar 28, 2015 8:51:18 GMT -5
So a thread on Yahoo regarding script numbers strongly suggests that while new script numbers aren't overwhelming, Novalog and others are way way down...because of the large number of Afrezza samples distributed.
|
|
|
Post by cybergym66 on Mar 28, 2015 9:12:12 GMT -5
So a thread on Yahoo regarding script numbers strongly suggests that while new script numbers aren't overwhelming, Novalog and others are way way down...because of the large number of Afrezza samples distributed. Yes, there's a thread here also suggesting the same thing. I think it's wishful thinking, but let's give it a few weeks before making that conclusion. A small snapshot of information (hello GS!) can cause inaccurate predictions (Hello GS again!).
|
|
|
Post by mnholdem on Mar 28, 2015 13:01:02 GMT -5
Permit me to make a slight correction. It's competing insulins Novolin and Humulin who had significant drops in scripts last week. Rapid Acting Analogs (RAA) such as Novalog, on the other hand, did not see a significant drop.
When the day/week comes that we start seeing sales drops among the analogs, and not just competing human insulins, then you can get really excited, since these synthetic insulins account for most of the mealtime market.
|
|